MenQuadfi

RSS

meningococcal group A, C, W-135 and Y conjugate vaccine

Authorised
This medicine is authorised for use in the European Union.

Overview

MenQuadfi is a vaccine used to protect adults and children from the age of 12 months against invasive meningococcal disease caused by four groups of the Neisseria meningitidis bacteria (group A, C, W, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning).

The vaccine contains substances from the outer coat of N. meningitidis bacteria.

This EPAR was last updated on 27/11/2020

Authorisation details

Product details
Name
MenQuadfi
Agency product number
EMEA/H/C/005084
Active substance
  • Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid
International non-proprietary name (INN) or common name
meningococcal group A, C, W-135 and Y conjugate vaccine
Therapeutic area (MeSH)
Meningitis, Meningococcal
Anatomical therapeutic chemical (ATC) code
J07AH08
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Sanofi Pasteur
Date of issue of marketing authorisation valid throughout the European Union
18/11/2020
Contact address

14 Espace Henry Vallée
69007 Lyon
France

Product information

18/11/2020 MenQuadfi - EMEA/H/C/005084 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

The use of this vaccine should be in accordance with available official recommendations.

Assessment history

How useful was this page?

Add your rating